Concerned Shareholder Bradley L. Radoff Urges Quipt Home Medical’s Board of Directors to Pursue a Value-Maximizing Sale

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Negative)

Tags

management

12/05/2025 - 04:00 PM

Questions Independent Director Mark Greenberg for His Role in Supporting Substantial Dilution of Shareholders and Rebuffing Inbound Interest

Intends to Vote Against Every Incumbent Director at 2026 Annual Meeting if the Board Continues to Put Shareholder Value at Risk

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff, who collectively with his affiliates owns approximately 4.9% of the outstanding common shares of Quipt Home Medical Corp. (NYSE: QIPT) ("Quipt" or the "Company"), today issued the following statement regarding the manner in which the Company’s Board of Directors (the “Board”) has failed to capitalize on apparent acquirer interest:

“The Board has spent years destroying its credibility by presiding over poor execution and significant shareholder value destruction. To make matters worse, after apparently receiving credible offers from an interested party earlier this year, the Board chose to dilute shareholders by awarding insiders approximately 6% of the Company. I am especially puzzled and concerned about the role of Director Mark Greenberg, who is a Managing Partner at boutique M&A advisory firm Silverstone Capital Advisors. On Silverstone’s website, it states ‘we are experts at putting a company up for sale and positioning it to attract the greatest number of interested potential acquirers.’ Based on public information, the Company seems to be attacking the only known bidder – it appears that Director Greenberg positions himself one way with clients and very differently on a Board that is entrenched.

At this point, the Board should immediately update the market on all efforts to maximize value. If the Board has not already done so, it should retain truly independent advisors and promptly pursue a value-maximizing sale process. Failure to take the right actions on behalf of shareholders will likely result in material changes to the Board at the 2026 Annual Meeting of Shareholders.

To be clear, I plan to vote all of my shares against every member of the Board if the status quo remains at the time of the 2026 Annual Meeting of Shareholders.”